Fulgent Genetics, Inc., together with its subsidiaries, provides genetic testing services to physicians with clinically actionable diagnostic information. Its technology platform integrates data comparison and suppression algorithms, learning software, and genetic diagnostics tools and integrated laboratory processes. The company primarily serves hospitals and medical institutions. It markets its tests through internal sales force, as well as through independent sales representatives in the United States, Canada, the People's Republic of China, and internationally. The company was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. Fulgent Genetics, Inc. was founded in 2011 and is headquartered in Temple City, California.
Industry, Sector and Symbol
Industry Medical laboratories
Sub-IndustryN/A
SectorMedical
Phone626-350-0537
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$18.73 million
Profitability
Miscellaneous
Employees98
OptionableNot Optionable
Fulgent Genetics (NASDAQ:FLGT) Frequently Asked Questions
What is Fulgent Genetics' stock symbol?
Fulgent Genetics trades on the NASDAQ under the ticker symbol "FLGT."
How were Fulgent Genetics' earnings last quarter?
Fulgent Genetics Inc (NASDAQ:FLGT) announced its earnings results on Monday, August, 6th. The company reported ($0.01) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.03) by $0.02. The company earned $5.40 million during the quarter, compared to the consensus estimate of $4.97 million. Fulgent Genetics had a negative net margin of 26.70% and a negative return on equity of 8.51%. View Fulgent Genetics' Earnings History.
When is Fulgent Genetics' next earnings date?
What price target have analysts set for FLGT?
2 analysts have issued 1-year target prices for Fulgent Genetics' stock. Their forecasts range from $5.00 to $5.10. On average, they expect Fulgent Genetics' stock price to reach $5.05 in the next year. This suggests a possible upside of 17.2% from the stock's current price. View Analyst Price Targets for Fulgent Genetics.
What is the consensus analysts' recommendation for Fulgent Genetics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Fulgent Genetics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Fulgent Genetics.
Has Fulgent Genetics been receiving favorable news coverage?
News stories about FLGT stock have been trending somewhat positive on Saturday, according to InfoTrie Sentiment. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Fulgent Genetics earned a media sentiment score of 1.2 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 2.0 out of 10, meaning that recent media coverage is very unlikely to have an impact on the company's share price in the next few days.
Who are some of Fulgent Genetics' key competitors?
Some companies that are related to Fulgent Genetics include Celcuity (CELC), Enzo Biochem (ENZ), Psychemedics (PMD), Miragen Therapeutics (MGEN), PotNetwork (POTN), First Choice Healthcare Solutions (FCHS), OpGen (OPGN), CBA Florida (CBAI), Cancer Genetics (CGIX), Aeon Global Health (AGHC), Biocept (BIOC) and Foundation Medicine (FMI).
Who are Fulgent Genetics' key executives?
Fulgent Genetics' management team includes the folowing people:
- Mr. Ming Hsieh, Chairman, CEO & Pres (Age 63)
- Mr. Paul Kim, Chief Financial Officer (Age 52)
- Dr. Han Lin Gao, Chief Scientific Officer & Lab Director (Age 52)
- Joe Roach, VP
When did Fulgent Genetics IPO?
(FLGT) raised $60 million in an IPO on Thursday, September 29th 2016. The company issued 4,600,000 shares at $12.00-$14.00 per share. Credit Suisse and Piper Jaffray acted as the underwriters for the IPO and Raymond James and BTIG were co-managers.
Who are Fulgent Genetics' major shareholders?
Fulgent Genetics' stock is owned by a variety of of retail and institutional investors. Top institutional investors include Old West Investment Management LLC (2.40%), Mutual Advisors LLC (1.08%), Essex Investment Management Co. LLC (0.46%), Essex Investment Management Co. LLC (0.46%), Royce & Associates LP (0.21%) and Brown Advisory Inc. (0.08%). Company insiders that own Fulgent Genetics stock include Ming Hsieh and Paul Kim. View Institutional Ownership Trends for Fulgent Genetics.
Which institutional investors are selling Fulgent Genetics stock?
Which institutional investors are buying Fulgent Genetics stock?
FLGT stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Essex Investment Management Co. LLC, Old West Investment Management LLC, Brown Advisory Inc. and Financial Advisors LLC. View Insider Buying and Selling for Fulgent Genetics.
How do I buy shares of Fulgent Genetics?
Shares of FLGT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Fulgent Genetics' stock price today?
One share of FLGT stock can currently be purchased for approximately $4.31.
How big of a company is Fulgent Genetics?
Fulgent Genetics has a market capitalization of $77.88 million and generates $18.73 million in revenue each year. The company earns $-2,510,000.00 in net income (profit) each year or ($0.11) on an earnings per share basis. Fulgent Genetics employs 98 workers across the globe.
What is Fulgent Genetics' official website?
How can I contact Fulgent Genetics?
Fulgent Genetics' mailing address is 4978 SANTA ANITA AVENUE, TEMPLE CITY CA, 91780. The company can be reached via phone at 626-350-0537 or via email at [email protected]
MarketBeat Community Rating for Fulgent Genetics (NASDAQ FLGT)
MarketBeat's community ratings are surveys of what our community members think about Fulgent Genetics and other stocks. Vote "Outperform" if you believe FLGT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FLGT will underperform the S&P 500 over the long term. You may vote once every thirty days.
